Akero Therapeutics, Inc. — Director's Dealing 2021

Oct 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2021-10-15

Reporting Person: Yale Catriona (Chief Development Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-15	Common Stock	S	12400	$21.58	Disposed	121021	Direct
2021-10-15	Common Stock	S	100	$22.34	Disposed	120921	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2020, as amended on June 11, 2021, previously adopted by the reporting person.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.29 to $22.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.